Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
157 hedge funds and large institutions have $1.07B invested in Revance Therapeutics, Inc. in 2022 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 46 increasing their positions, 59 reducing their positions, and 17 closing their positions.
169% more call options, than puts
Call options by funds: $27.5M | Put options by funds: $10.2M
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
23% more capital invested
Capital invested by funds: $865M → $1.07B (+$201M)
4% more funds holding
Funds holding: 151 → 157 (+6)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
22% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 59
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$9.2M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$5.96M |
| 3 |
D.E. Shaw & Co
New York
|
+$4.89M |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$4.03M |
| 5 |
Jennison Associates
New York
|
+$3.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.5M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$5.49M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.56M |
| 4 |
Goldman Sachs
New York
|
-$2.27M |
| 5 |
JP Morgan Chase
New York
|
-$1.66M |
RVNC Hedge Fund Activity: Q1 2022 in Review
157 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2022, worth a combined $1.07B — up 23% from $865M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new RVNC positions and 17 closed out — a net gain of 7 holders — while 46 added to existing stakes and 59 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $9.2M. The largest seller was Wellington Management Group, cutting an estimated $10.5M.
- 157 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2022, up from 151 in Q4 2021.
- Funds reported $1.07B of Revance Therapeutics, Inc. stock for Q1 2022, up 23% quarter-over-quarter.
- 24 funds opened new Revance Therapeutics, Inc. positions in Q1 2022 and 17 closed out, a net change of +7 holders.
- The largest Revance Therapeutics, Inc. buyer in Q1 2022 was Citadel Advisors, an estimated $9.2M added.
- The largest Revance Therapeutics, Inc. seller in Q1 2022 was Wellington Management Group, an estimated $10.5M sold.
Based on aggregated 13F filings for Q1 2022.